[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN110546150A - 含吡唑基的三并环类衍生物、其制备方法和应用 - Google Patents

含吡唑基的三并环类衍生物、其制备方法和应用 Download PDF

Info

Publication number
CN110546150A
CN110546150A CN201880008491.0A CN201880008491A CN110546150A CN 110546150 A CN110546150 A CN 110546150A CN 201880008491 A CN201880008491 A CN 201880008491A CN 110546150 A CN110546150 A CN 110546150A
Authority
CN
China
Prior art keywords
group
alkyl
heteroaryl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880008491.0A
Other languages
English (en)
Other versions
CN110546150B (zh
Inventor
刘世强
周远锋
刘扬
吴雪松
刘磊
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN110546150A publication Critical patent/CN110546150A/zh
Application granted granted Critical
Publication of CN110546150B publication Critical patent/CN110546150B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明涉及含吡唑基的三并环类衍生物、其制备方法和应用。特别地，本发明涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为蛋白酶如ERK(MAPK)抑制剂在治疗癌症、骨病、炎性疾病、免疫疾病、神经系统疾病、代谢性疾病、呼吸性疾病和心脏病的用途，其中通式(I)中的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201880008491.0A 2017-10-19 2018-10-18 含吡唑基的三并环类衍生物、其制备方法和应用 Active CN110546150B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201710979926 2017-10-19
CN2017109799263 2017-10-19
CN2018100238179 2018-01-10
CN201810023817 2018-01-10
CN201810882539 2018-07-30
CN2018108825392 2018-07-30
PCT/CN2018/110795 WO2019076336A1 (zh) 2017-10-19 2018-10-18 含吡唑基的三并环类衍生物、其制备方法和应用

Publications (2)

Publication Number Publication Date
CN110546150A true CN110546150A (zh) 2019-12-06
CN110546150B CN110546150B (zh) 2021-12-21

Family

ID=66173535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880008491.0A Active CN110546150B (zh) 2017-10-19 2018-10-18 含吡唑基的三并环类衍生物、其制备方法和应用

Country Status (6)

Country Link
US (1) US20200247815A1 (zh)
EP (1) EP3699179A4 (zh)
JP (1) JP2020537669A (zh)
CN (1) CN110546150B (zh)
TW (1) TW201917129A (zh)
WO (1) WO2019076336A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114621230A (zh) * 2020-12-10 2022-06-14 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164761A (zh) 2018-10-05 2021-07-23 弗特克斯药品有限公司 α-1抗胰蛋白酶的调节剂
WO2020200161A1 (zh) * 2019-04-02 2020-10-08 上海翰森生物医药科技有限公司 含吲唑基的三并环类衍生物的盐及其晶型
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TW202116303A (zh) * 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—１抗胰蛋白酶缺乏症之治療方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352931A (en) * 1980-05-22 1982-10-05 Siegfried Aktiengesellschaft Lin-benzoaminopurinols
JP2004203804A (ja) * 2002-12-26 2004-07-22 Taiho Yakuhin Kogyo Kk 新規なインダゾール誘導体又はその塩及びそれらを有効成分とする医薬
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
WO2014179154A2 (en) * 2013-04-30 2014-11-06 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN105636586A (zh) * 2013-10-03 2016-06-01 库拉肿瘤学公司 Erk抑制剂及使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025515A2 (en) * 2003-09-12 2005-03-24 California Institute Of Technology Proteasome pathway inhibitors and related methods
CN102140099A (zh) * 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
EP2655350B1 (en) 2010-12-21 2016-03-09 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
WO2014134776A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2014137728A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015051314A2 (en) 2013-10-04 2015-04-09 Clique Intelligence Systems and methods for enterprise management using contextual graphs
TW201805000A (zh) * 2016-06-20 2018-02-16 庫拉腫瘤技術股份有限公司 利用erk抑制劑之鱗狀細胞癌之治療

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352931A (en) * 1980-05-22 1982-10-05 Siegfried Aktiengesellschaft Lin-benzoaminopurinols
JP2004203804A (ja) * 2002-12-26 2004-07-22 Taiho Yakuhin Kogyo Kk 新規なインダゾール誘導体又はその塩及びそれらを有効成分とする医薬
WO2007056155A1 (en) * 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
WO2014179154A2 (en) * 2013-04-30 2014-11-06 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN105636586A (zh) * 2013-10-03 2016-06-01 库拉肿瘤学公司 Erk抑制剂及使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EL-REMAILY, M.A.E.A.A.A.等: "Synthesis and in vitro Antibacterial Activity of Some Novel Fused Pyridopyrimidine Derivatives", 《J. HETEROCYCLIC CHEM.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114621230A (zh) * 2020-12-10 2022-06-14 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用
CN114621230B (zh) * 2020-12-10 2023-06-16 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
JP2020537669A (ja) 2020-12-24
US20200247815A1 (en) 2020-08-06
CN110546150B (zh) 2021-12-21
WO2019076336A1 (zh) 2019-04-25
EP3699179A1 (en) 2020-08-26
EP3699179A4 (en) 2021-06-16
TW201917129A (zh) 2019-05-01

Similar Documents

Publication Publication Date Title
CN110546150B (zh) 含吡唑基的三并环类衍生物、其制备方法和应用
CN103261167B (zh) 取代的6，6-稠合含氮杂环化合物及其用途
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
WO2020253862A1 (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
JP2022504352A (ja) 窒素を含有するヘテロ芳香族誘導体の制御因子、その製造方法及び使用
WO2022206723A1 (zh) 杂环类衍生物、其制备方法及其医药上的用途
CN115594666A (zh) 一种磷酸酶降解剂的合成和应用
CN112552294A (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
CN113072551B (zh) 含氮联苯类衍生物抑制剂、其制备方法和应用
WO2022121914A1 (zh) 氧代氮环类衍生物调节剂、其制备方法和应用
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
WO2020233669A1 (zh) 含吲哚类衍生物抑制剂、其制备方法和应用
EP4452963A1 (en) Parp1 inhibitors
TW202016120A (zh) 含三并環類衍生物抑制劑、其製備方法和應用
CN113164475A (zh) Dyrk1a的大环抑制剂
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2020200069A1 (zh) 吡咯并杂环类衍生物、其制备方法及其在医药上的应用
EP4358954A1 (en) Cdk2 inhibitors and methods of using the same
WO2020020385A1 (zh) 含三并环类衍生物抑制剂、其制备方法和应用
WO2021032004A1 (zh) 氮杂芳基化合物及其应用
WO2020192750A1 (zh) 噻吩并杂环类衍生物、其制备方法及其在医药上的应用
WO2022105921A1 (zh) 一类嘧啶并杂环类化合物、制备方法和用途
CN109761986B (zh) 三并环类衍生物抑制剂、其制备方法和应用
CN112020357A (zh) 含吲唑基的三并环类衍生物的盐及其晶型
WO2021249417A1 (zh) 杂环化合物及其衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant